Karen L. Milkiewicz - Concepedia

Concepedia

Author

Karen L. Milkiewicz

Johnson & Johnson (United States)

Also Known As

K.L. Milkiewicz, Karen L Milkiewicz, Karen L. Milkiewicz

25

Publications

1.2K

Citations

16

H-Index

35

Concepts

All Affiliations

Johnson & Johnson (United States)Avalon Pharma (United States)University at Buffalo, State University of New York

KL

About

Karen L. Milkiewicz is an author at Johnson & Johnson (United States) specializing in medicine, pharmacology, and natural sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	1K
2	Natural Sciences	11	11	949
3	Biochemistry	7	7	584
4	Biomolecular Engineering	4	4	550
5	Engineering	2	2	37

Karen L. Milkiewicz

×

16

Publications

1.2K

Citations

14

H-Index

	Year	Citations
Discovery and Cocrystal Structure of Benzodiazepinedione HDM2 Antagonists That Activate p53 in Cells Bruce Grasberger, Tianbao Lu, Carsten J. Schubert, Journal of Medicinal Chemistry Molecular BiologyChemical BiologyPharmaceutical ChemistryTumor BiologyMolecular Pharmacology	2005	425
1,4-Benzodiazepine-2,5-diones as small molecule antagonists of the HDM2–p53 interaction: discovery and SAR Daniel J. Parks, Louis V. LaFrance, Raul R. Calvo, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologyDrug TargetSmall Molecule AntagonistsMedicineNatural Sciences	2004	166
Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation <i>in vitro</i> and sensitize tumors to doxorubicin <i>in vivo</i> Holly K. Koblish, Shuyuan Zhao, Carol F. Franks, Molecular Cancer Therapeutics P53 InteractionChemoprevention StrategyP53 ComplexTumor BiologyMedicinal Chemistry	2006	162
Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein–protein interaction through structure-based drug design Daniel J. Parks, Louis V. LaFrance, Raul R. Calvo, Bioorganic & Medicinal Chemistry Letters Hdm2-p53 Protein–protein InteractionDrug TargetMedicineRational Drug DesignStructure-based Drug Design	2006	76
A Selective, Orally Bioavailable 1,2,4-Triazolo[1,5-<i>a</i>]pyridine-Based Inhibitor of Janus Kinase 2 for Use in Anticancer Therapy: Discovery of CEP-33779 Benjamin J. Dugan, Diane E. Gingrich, Eugen F. Mesaros, Journal of Medicinal Chemistry	2012	62
7-Fluoroindazoles as Potent and Selective Inhibitors of Factor Xa Yu‐Kai Lee, Daniel J. Parks, Tianbao Lu, Journal of Medicinal Chemistry Bioorganic ChemistryPharmacotherapyChemical BiologyPharmaceutical ChemistryMedicinal Chemistry	2007	55
Synthesis and structure–activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase Karen L. Milkiewicz, Linda R. Weinberg, Mark S. Albom, Bioorganic & Medicinal Chemistry Pharmaceutical ChemistryMedicineSelective InhibitorsAnti-cancer AgentStructure–activity Relationships	2010	30
The design, synthesis and activity of non-ATP competitive inhibitors of pp60c-src tyrosine kinase. Part 2: Hydroxyindole derivatives Karen L. Milkiewicz, Thomas H. Marsilje, Richard P. Woodworth, Bioorganic & Medicinal Chemistry Letters Hydroxyindole DerivativesPp60c-src Tyrosine KinaseMedicinal ChemistryPharmaceutical ScienceBioorganic Chemistry	2000	30
Synthesis of a novel series of tetra-substituted furan[3,2-b]pyrroles Karen L. Milkiewicz, Daniel J. Parks, Tianbao Lu Tetrahedron Letters Novel SeriesOrganic ChemistryChemistryHeterocycle ChemistrySynthetic Chemistry	2003	24
Fused bicyclic derivatives of 2,4-diaminopyrimidine as c-Met inhibitors Linda R. Weinberg, Mark S. Albom, Thelma S. Angeles, Bioorganic & Medicinal Chemistry Letters Combinatorial ChemistryMedicinal ChemistryBicyclic DerivativesNatural SciencesMedicine	2010	23

Page 1